GV29893 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

Project: Other project

StatusFinished
Effective start/end date10/27/1610/26/18

Funding

  • Genentech, Inc.: $3,846.15